…
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Motus GI Holdings Inc is a medical device company developing and commercializing endoscopy tools, principally a colon-cleansing system designed for use during colonoscopy procedures. Long-term growth may be supported by rising colorectal screening demand, broader adoption in hospitals and ambulatory surgery centers, and potential procedural benefits such as improved mucosal visualization and fewer repeat exams. The technology appears positioned to address a clear clinical need that could support market uptake if commercial execution and reimbursement progress.
Key risks include execution and commercialization challenges, reimbursement and regulatory uncertainty, competition from alternative bowel-prep and endoscopy technologies, and limited liquidity and financing flexibility as an OTCQB-listed company.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -12.87M | -18.60M | -19.03M | -19.26M | -23.09M |
| Net income | -12.87M | -18.09M | -18.91M | -19.60M | -22.59M |
| Selling general administrative | 6.58M | 7.61M | 9.27M | 9.56M | 9.50M |
| Selling and marketing expenses | 1.61M | 4.42M | 3.08M | 3.53M | 4.90M |
| Gross profit | -0.59M | -0.20M | -0.23M | -0.40M | -0.03M |
| Reconciled depreciation | 0.68M | 0.84M | 0.70M | 0.38M | 0.22M |
| Ebit | -11.91M | -17.85M | -17.92M | -19.05M | -23.44M |
| Ebitda | -11.23M | -17.30M | -18.06M | -18.79M | -23.43M |
| Depreciation and amortization | 0.68M | 0.55M | -0.14M | 0.26M | 0.00M |
| Non operating income net other | - | - | - | -0.00M | -0.00M |
| Operating income | -11.91M | -17.85M | -17.92M | -19.05M | -23.44M |
| Other operating expenses | 12.23M | 18.44M | 18.32M | 19.14M | 23.54M |
| Interest expense | 0.76M | 1.25M | 0.72M | 0.46M | 0.00M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | - | - | - | - | 0.27M |
| Net interest income | -0.76M | -1.25M | -0.72M | -0.46M | 0.27M |
| Income tax expense | - | -0.51M | -0.12M | 0.34M | -0.49M |
| Total revenue | 0.32M | 0.59M | 0.39M | 0.10M | 0.11M |
| Total operating expenses | 11.32M | 17.65M | 17.69M | 18.65M | 23.41M |
| Cost of revenue | 0.91M | 0.80M | 0.62M | 0.50M | 0.14M |
| Total other income expense net | -0.96M | -0.75M | -1.11M | -0.21M | 0.35M |
| Net income from continuing ops | -12.87M | -18.60M | -19.03M | -19.26M | -23.09M |
| Net income applicable to common shares | - | - | -25.18M | -19.26M | -23.09M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 7.22M | 17.65M | 26.09M | 24.06M | 32.26M |
| Other current assets | 0.48M | 0.78M | 0.79M | 0.45M | 0.34M |
| Total liab | 4.54M | 14.67M | 16.43M | 12.77M | 13.93M |
| Total stockholder equity | 2.69M | 2.98M | 9.66M | 11.29M | 18.33M |
| Other current liab | 0.23M | 0.05M | 2.59M | 2.39M | 3.27M |
| Common stock | - | - | 0.01M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.01M | 0.00M | 0.00M |
| Retained earnings | -154.22M | -141.35M | -122.75M | -103.72M | -84.46M |
| Other liab | - | - | 1.76M | 1.62M | 1.87M |
| Other assets | - | - | 0.01M | 0.00M | 0.01M |
| Cash | 4.96M | 14.04M | 22.56M | 20.82M | 20.53M |
| Total current liabilities | 3.27M | 4.80M | 2.90M | 10.61M | 11.34M |
| Net debt | -2.49M | -2.61M | -10.48M | -12.05M | -11.74M |
| Short term debt | 1.20M | 2.78M | 0.31M | 8.22M | 8.07M |
| Short long term debt | 1.03M | 2.53M | - | 7.98M | 7.75M |
| Short long term debt total | 2.47M | 11.44M | 12.08M | 8.76M | 8.79M |
| Other stockholder equity | 156.91M | 144.33M | 132.41M | 115.01M | 102.79M |
| Property plant equipment | - | - | 2.12M | 1.94M | 2.08M |
| Total current assets | 5.76M | 15.37M | 23.96M | 22.11M | 30.17M |
| Net tangible assets | - | - | 9.66M | 11.29M | 18.33M |
| Short term investments | - | - | - | 0.00M | 8.20M |
| Net receivables | 0.08M | 0.06M | 0.11M | 0.04M | 0.08M |
| Long term debt | 1.24M | 8.48M | 11.39M | - | - |
| Inventory | 0.24M | 0.49M | 0.50M | 0.81M | 1.01M |
| Accounts payable | 1.84M | 1.97M | 2.58M | 0.00M | 3.00M |
| Accumulated other comprehensive income | - | - | - | - | -0.63M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -103.72M | -84.46M |
| Non currrent assets other | 0.26M | 0.52M | 0.01M | 0.01M | 0.01M |
| Non current assets total | 1.47M | 2.28M | 2.13M | 1.96M | 2.09M |
| Capital lease obligations | 0.20M | 0.42M | 0.69M | 0.79M | 1.03M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -0.10M | -0.22M | -0.47M | 8.12M | 4.50M |
| Change to liabilities | - | - | 0.30M | -0.49M | 0.39M |
| Total cashflows from investing activities | - | - | -0.47M | 8.12M | -5.62M |
| Net borrowings | -4.96M | - | 3.78M | -0.03M | 8.00M |
| Total cash from financing activities | 2.41M | 9.17M | 16.64M | 9.17M | 28.02M |
| Change to operating activities | - | - | -0.72M | -0.55M | -0.10M |
| Net income | -12.87M | -18.60M | -19.03M | -19.26M | -23.09M |
| Change in cash | -9.08M | -8.52M | 1.74M | 0.29M | 2.48M |
| Begin period cash flow | 14.04M | 22.56M | 20.82M | 20.53M | 18.05M |
| End period cash flow | 4.96M | 14.04M | 22.56M | 20.82M | 20.53M |
| Total cash from operating activities | -11.39M | -17.47M | -14.42M | -16.99M | -19.91M |
| Issuance of capital stock | 8.66M | 10.25M | 1.90M | 9.99M | 20.00M |
| Depreciation | 0.68M | 0.84M | 0.70M | 0.38M | 0.22M |
| Other cashflows from investing activities | - | - | - | - | -9.65M |
| Dividends paid | 1.48M | - | - | - | - |
| Change to inventory | 0.00M | -1.30M | -0.27M | -0.62M | -0.97M |
| Change to account receivables | -0.02M | 0.05M | -0.07M | 0.03M | -0.06M |
| Sale purchase of stock | -0.01M | -0.01M | - | 0.06M | 20.00M |
| Other cashflows from financing activities | 1.49M | -0.37M | 22.96M | -0.82M | 8.02M |
| Change to netincome | - | - | 4.84M | 3.49M | 3.31M |
| Capital expenditures | 0.10M | 0.22M | 0.47M | 0.09M | 0.47M |
| Change receivables | - | - | - | 0.05M | -0.06M |
| Cash flows other operating | - | - | - | 0.21M | 0.28M |
| Cash and cash equivalents changes | - | - | - | 0.29M | 2.48M |
| Change in working capital | -0.41M | -2.18M | -0.77M | -1.63M | -0.51M |
| Stock based compensation | 0.47M | 2.04M | 3.71M | 3.07M | 3.21M |
| Other non cash items | 0.26M | 0.43M | 0.29M | 0.03M | 0.14M |
| Free cash flow | -11.50M | -17.69M | -14.89M | -17.08M | -20.38M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MOTS Motus GI Holdings Inc |
- -% |
0.00 | - | - | 0.00 | - | 4.58 | 0.03 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
1301 East Broward Boulevard, Fort Lauderdale, FL, United States, 33301
954 541 8000
15
| Name | Title | Year Born |
|---|---|---|
| Mr. Timothy P. Moran | CEO & Director | 1972 |
| Mr. Mark Pomeranz | Pres, COO & Director | 1962 |
| Mr. Andrew Lawrence Taylor M.B.A. | Chief Financial Officer | 1972 |
| Mr. Scott C. Aldrich Jr. | VP of Global Marketing & Strategy | NA |
| Ms. Ravit Ram | CFO & VP of Global Operations | 1975 |
| Mr. Elad Amor | Chief Accounting Officer | 1984 |
| Jeff Varsalone | President & Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.